NCT02011672

Brief Summary

Background: Recent advances in science have established a fundamental role for low grade chronic inflammation in mediating all stages of most of the non-communicable diseases associated with ageing. Pro-inflammatory effects of hyperglycemia have been described. Dairy and its components are known to exert beneficial effects on postprandial hyperglycemia. This study investigates if dairy, normal and enriched, can reduce chronic inflammation via improvement in glucose regulation. Objective: To compare the effect of a nutrient-enriched dairy drink on parameters of glucose regulation and postprandial inflammation with the effect of a standard milk drink, within a population of overweight, apparently healthy subjects. Study design: The study is designed as a double-blind randomized placebo-controlled parallel trial during 7 weeks, during which the test and reference products will be consumed at home. Main study parameters/endpoints: The difference in absolute change in fasting blood plasma concentration of glucose, insulin and IL-6, from baseline to endpoint, and the difference in postprandial response of plasma concentration of glucose, insulin and IL-6 at the end of the treatment period, between subjects consuming the test and reference product.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2013

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2013

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

December 10, 2013

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 13, 2013

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2014

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2014

Completed
Last Updated

September 9, 2014

Status Verified

September 1, 2014

Enrollment Period

5 months

First QC Date

December 10, 2013

Last Update Submit

September 8, 2014

Conditions

Keywords

dairyglucoseinflammation

Outcome Measures

Primary Outcomes (2)

  • change in fasting blood glucose

    baseline and 7 weeks

  • change in fasting plasma interleukin-6 (IL-6)

    baseline and 7 weeks

Secondary Outcomes (4)

  • postprandial area under the curve for plasma glucose

    7 weeks

  • change in fasting insulin

    7 weeks

  • postprandial area under the curve for plasma insulin

    7 weeks

  • postprandial area under the curve for plasma IL-6

    7 weeks

Study Arms (2)

nutrient-enriched milk

EXPERIMENTAL

consumption of 250 ml three times per day

Other: nutrient-enriched milk

regular milk

PLACEBO COMPARATOR

consumption of 250 ml three times per day

Other: regular milk

Interventions

nutrient-enriched milk
regular milk

Eligibility Criteria

Age50 Years - 65 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • BMI 28-35 kg/m2
  • Waist circumference \>102 cm
  • Healthy as assessed by the NIZO lifestyle and health questionnaire and results of the pre-study safety laboratory tests.
  • Regular and normal Dutch eating habits as assessed by the NIZO lifestyle and health questionnaire (3 main meals per day)
  • Habitual consumption of dairy products as assessed by dietary questionnaire
  • Voluntary participation
  • Having given written informed consent
  • Willing to comply with study procedures
  • Access to internet
  • Willing to accept use of all encoded data, including publication, and the confidential use and storage of all data for at least 15 years.
  • Willing to accept disclosure of the financial benefit of participation in the study to the authorities concerned

You may not qualify if:

  • Participation in any clinical trial including blood sampling and/or administration of substances up to 90 days before Day 01 of this study
  • Participation in any non-invasive clinical trial up to 30 days before Day 01 of this study, including no blood sampling and/or oral, intravenous or inhalatory administration of substances
  • Having a history of medical or surgical events that may significantly affect the study outcome, including: Inflammatory bowel disease, ulcers, gastrointestinal or rectal bleeding; major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection; known or suspected gastrointestinal strictures
  • Medical drug use; antibiotics, laxatives, glucose lowering drugs, insulin; all medication with an inflammation inhibiting effect (e.g. NSAIDS, corticosteroids) and/or an effect on blood coagulation (e.g. coumarins, inhibitors of thrombin or factor Xa, acetylsalicylic acid, antidepressants from the group of serotonin reabsorption inhibitors, tranexamin acid)
  • Mental status that is incompatible with the proper conduct of the study
  • A self-reported reported food allergy or sensitivity (wheat, milk, lactose, eggs, nuts, etc)
  • Alcohol consumption \> 28 units/week and 4/day
  • Exercise \> 3 hours/week
  • Smoking \>20 cigarettes/day
  • Reported unexplained weight loss or weight gain of \> 3 kg in the month prior to pre-study screening
  • Reported slimming or medically prescribed diet
  • Reported vegan or macrobiotic life-style
  • Recent blood donation (\<1 month prior to Day 01 of the study)
  • Not willing or afraid to give up blood donation during the study
  • Personnel of NIZO food research or Wageningen University, department of Human Nutrition, their partner and their first and second degree relatives
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NIZO food research

Ede, Netherlands

Location

MeSH Terms

Conditions

Inflammation

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Alwine Kardinaal, PhD

    NIZO Food Research

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Project Manager Health

Study Record Dates

First Submitted

December 10, 2013

First Posted

December 13, 2013

Study Start

November 1, 2013

Primary Completion

April 1, 2014

Study Completion

June 1, 2014

Last Updated

September 9, 2014

Record last verified: 2014-09

Locations